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Experimental Study Concerning Safety Dosage of 
OK-432 for Intrauterine Treatment
Keiko Ogita, Tomoaki Taguchi and Sachiyo Suita, Department of Pediatric Surgery, Graduate School of 
Medical Sciences, Kyushu University, Fukuoka, Japan.
OBJECTIVE: Clinical intrauterine treatment for fetal cystic hygroma has so far been performed in a few
patients; however, it is still difficult to evaluate the results. The aim of this study is to establish the safe
dosage of OK-432 in the intrauterine treatment of fetal cystic hygroma.
METHODS: OK-432 was injected either subcutaneously behind the neck of the fetuses or into the amni-
otic cavity through the uterine wall of pregnant Japanese white rabbits at 27 days of gestation. Saline was
administered to the controls. The dosage and the site of injection were as follows: group 1, OK-432,
0.01 KE (0.25 KE/kg) in 0.2 mL saline per fetus, subcutis; group 2, OK-432, 0.02 KE (0.5 KE/kg) in 0.2 mL
saline per fetus, subcutis; group 3, OK-432, 0.04 KE (1 KE/kg) in 0.2 mL saline per fetus, subcutis; group
4, OK-432, 0.01 KE in 0.2 mL saline per fetus, amniotic cavity; group 5, OK-432, 0.04 KE in 0.2 mL saline
per fetus, amniotic cavity; group 6, saline, 0.2 mL per fetus, subcutis; group 7, saline, 0.2 mL per fetus,
amniotic cavity. All fetuses were delivered at 29 days of gestation.
RESULTS: The mother’s rectal temperature was mostly in the normal range throughout the experiment.
There was no significant difference between any of the seven groups in fetal body weight. The C reactive
protein values of all fetuses were negative. The appearance of the skin of all the fetuses was normal. The
histopathological findings of the skin in the OK-432 groups showed a moderate infiltration of mono-
cytes and plasma cells. No pathological changes were observed in the heart, lung, liver or kidneys of any
of the fetuses.
CONCLUSION: Based on this rabbit experiment, we determined that OK-432 may be safely used at a
dose of up to 1 KE/1 kg of fetal body weight as an intrauterine treatment for fetal cystic hygroma. [Asian J
Surg 2006;29(3):202–6]
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Introduction
Fetal cystic hygroma is a congenital malformation of 
the lymphatic system, appearing most often around the
neck.1 Cases of cystic hygroma, with a huge neck mass, are
at risk of developing airway obstruction, which can result
in death, while cases associated with hydrops fetalis are 
at  risk of suffering from intrauterine fetal death due to 
circulatory failure.2,3 Intrauterine treatment for cystic
hygroma using OK-432, which is a biological response modi-
fier with an anti-tumour effect and is used in sclerotherapy
to treat neonatal cystic hygroma, has recently begun to be
used clinically in order to overcome this severe condition.
However, there have so far been only a few reports on this
treatment modality.3–8 The indications and safety have also
not yet been established. Therefore, the aim of this study is
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to establish the safe dosage levels of OK-432 for the
intrauterine treatment of fetal cystic hygroma, referring to
the practical dosages of human neonatal cases. This is the
first report to evaluate the safe dosages of OK-432 using 
animal fetal models.
Materials and methods
Pregnant Japanese white rabbits (body weight, 3.8–4.0 kg)
were obtained (Kyudo Co., Saga, Japan). At 27 days of ges-
tation (full term, 31 days), the operation was performed
under sodium pentobarbital intravenous anaesthesia
(35 mg/kg) as follows: after carrying out a median laparo-
tomy, the entire uterus was exposed from the abdominal
cavity. OK-432 (Picibanil®, Chugai Pharmaceutical Co.,
Tokyo, Japan) was then administered to the fetus by a
transuterine puncture using a 27-gauge needle. The sites
administered OK-432 included the subcutaneous tissue
behind the neck of the fetuses or the amniotic cavity. The
experimental groups were classified into seven groups
according to the site and dosage (Table). Regarding the
dosage of OK-432, we administered 0.027 KE of OK-432
to a rabbit fetus weighing 40 g, based on the calculations
in which a neonate weighing 3,000 g is administered 2 KE
of OK-432 (0.67 KE/kg) as a maximal volume. Therefore,
we administered OK-432 at dosages ranging from 0.01 KE
(0.25 KE/kg) to 0.04 KE (1 KE/kg) for each fetus. The
groups, in which OK-432 was injected into the amniotic
fluid, were studied regarding any adverse effects caused
by OK-432 in the case of leakage into the amniotic fluid.
OK-432 was dissolved by saline and the administration
volume was 0.2 mL for each group. The pregnancy was
allowed to continue until 29 days of gestation, and all
fetuses were then delivered by caesarean section. The
mother’s rectal temperature was measured before opera-
tion, immediately after operation, and at 1, 2 and 24 hours
after operation, and just before the caesarean section. The
fetuses were weighed and blood was aspirated to measure
the C reactive protein (CRP) values. Next, the fetuses were
sacrificed and a part of their lung, heart, liver, kidney and
skin at the site of injection was fixed with 10% formalde-
hyde and examined with haematoxylin-eosin staining.
All results are expressed as mean ± SD. An unpaired 
t test was used for the statistical analysis. The level of sig-
nificance was set at p < 0.05.
This experiment was reviewed by the Committee on
the Ethics of Animal Experiments in the Graduate School
of Medical Sciences, Kyushu University and it was carried
out under the Guidelines for Animal Experiments in
Kyushu University.
Results
The mother rabbits and fetuses were all alive throughout
the experimental period. The rectal body temperature of
the mothers was mostly in the normal range during the
experiment in all groups except for the rectal temperature
just after the operation, which was slightly below the nor-
mal range (Figure 1).
The mean body weight of the fetuses showed no sig-
nificant difference among groups. Serum CRP levels of all
fetuses were below 0.6 mg/dL. However, the mean CRP
value of group 3, which was injected with 0.04 KE of OK-
432 subcutaneously, was the highest. There was no statis-
tically significant difference between any of the groups
(Table).
Table. Dose and site of administration, and summary of results
Volume
Calculated Mean body Serum Infiltration of 
Group Medication Injected part
(per fetus)
dose (KE/ weight of C reactive inflammatory 
kg fetus) fetus (g) protein (mg/dL) cells
1 (n= 6) OK-432 Subcutis 0.01 KE 0.25 38.5 ± 3.15 0.13 ± 0.05 +
2 (n= 9) OK-432 Subcutis 0.02 KE 0.5 37.0 ± 11.5 0.17 ± 0.13 +
3 (n= 8) OK-432 Subcutis 0.04 KE 1.0 40.1 ± 4.52 0.34 ± 0.32 +
4 (n= 4) OK-432 Amniotic cavity 0.01 KE 0.25 39.5 ± 4.20 0.15 ± 0.06 –
5 (n= 8) OK-432 Amniotic cavity 0.04 KE 1.0 41.5 ± 2.88 0.14 ± 0.05 –
6 (n= 6) Saline Subcutis 0.2 mL 0 34.2 ± 5.85 0.13 ± 0.05 –
7 (n= 4) Saline Amniotic cavity 0.2 mL 0 40.0 ± 4.08 0.10 ± 0.0 –
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The macroscopic findings of the nuchal skin injected
with saline or OK-432 showed a normal appearance in 
all fetuses (Figures 2A and B). The systemic skin of all
fetuses injected with OK-432 into the amniotic cavity 
also showed a normal appearance. The histopathological
findings of the nuchal skin injected with saline were
almost normal in appearance (Figure 2C). In contrast, the
histopathological findings of the nuchal skin injected
with OK-432 showed a moderate infiltration of mono-
cytes and plasma cells (Figure 2D), and no significant 
difference was observed in the degree of infiltration 
of inflammatory cells dependent on the dosage. The
histopathological findings of the nuchal skin injected
with OK-432 into the amniotic cavity showed a normal
appearance.
The macroscopic and histopathological findings of
the heart, lung, liver and kidney of the fetuses showed a
normal appearance in all groups.
Discussion
OK-432 has been reported to have several adverse effects,
including fever and fatigue as general conditions, and 
tenderness, swelling, reddening and induration as local
findings. An increased white blood cell count and
increased CRP level have also been commonly observed.9
In this study, all mother rabbits and fetuses remained
alive throughout the experimental period without any
spontaneous abortions. In addition, no fetuses showed
any toxic responses considered to be an adverse effect
related to OK-432.
Regarding the dosage, OK-432 has been reported to be
administered at a range of 1–2 KE at a concentration of
1 KE/1 mL of saline in neonates.10 In this study, based on
the calculations in which a neonate weighing 3,000 g is
administered 2 KE of OK-432 (0.67 KE/kg) as a maximal
volume, a rabbit fetus of 40 g is administered OK-432 of
0.027 KE. Therefore, we administered OK-432 at dosages
ranging from 0.01 KE (0.25 KE/kg) to 0.04 KE (1 KE/kg)
for each fetus. Moreover, the groups, in which OK-432 was
injected into the amniotic fluid, were studied regarding
any adverse effects caused by OK-432 in case of leakage
into the amniotic fluid. The volume of injection was
determined considering about the equality among each
group and the concentration. Regarding the mothers in
this study, the maximal dosage of OK-432 for the moth-
ers was 0.08 KE/kg and no adverse effects were observed,
including fever. This dosage equals that for a fetus of a
pregnant woman, who weighs 55 kg in body weight and is
administered OK-432 at a dose of 4.4 KE.
On the other hand, the mean CRP value of group 3
was the highest and the histopathological findings of
group 3 showed a mild infiltration of inflammatory cells,
which consisted of either plasma cells or monocytes.
These findings might be consistent with those of inflam-
matory effect of OK-432. Moreover, there have been
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Figure 1. The changes in the mothers’ rectal tem-
perature. The temperatures were mostly in the 
normal range during the experiment in all groups,
except for the rectal temperature just after the
operation, which was slightly below the normal
range. The normal temperature range was 38.65 ±
0.73°C.
reported effective neonatal cases treated by the dosage 
of OK-432, which was 1 KE/kg.2,10 Therefore, we suggest
that the dosage, 1 KE/kg, of OK-432 is appropriate to
treat fetal cystic hygroma.
In conclusion, no adverse effects were observed in either
the mothers or the fetuses when OK-432 was injected into
the fetuses either subcutaneously or into the amniotic
cavity at a dose of up to 1 KE/1 kg of the fetal rabbit’s body
weight. Our above findings therefore suggest that human
intrauterine treatment of fetal cystic hygroma by the
administration of OK-432 is a safe and effective therapeu-
tic modality.
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Figure 2. Macroscopic findings of nuchal skin in (A) group 6 and (B) group 3 show a mostly normal appearance. Histopathological
findings of nuchal skin in (C) group 6 show a mostly normal appearance and those in (D) group 3 show moderate infiltration of inflam-
matory cells, such as plasma cells (arrows) and monocytes in the subcutaneous tissue (haematoxylin and eosin, 200×).
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